In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
The New England Journal of Medicine: Search Results in Cardiology
Asundexian versus Apixaban in Patients with Atrial Fibrillation
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.
The New England Journal of Medicine: Search Results in Cardiology
Atrial Fibrillation and Stable Coronary Artery Disease
Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. However, atrial fibrillation commonly coexists with vascular diseases, such as coronary artery disease. When patients with both conditions present with…
The New England Journal of Medicine: Search Results in Cardiology
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
The New England Journal of Medicine: Search Results in Cardiology
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
In this multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.
The New England Journal of Medicine: Search Results in Cardiology
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Asundexian versus Apixaban in Patients with Atrial Fibrillation
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation
In a randomized trial involving patients with heart failure and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral-valve surgery at 1-year follow-up.
The New England Journal of Medicine: Search Results in Cardiology
PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation
In a trial of percutaneous coronary intervention or conservative treatment in patients undergoing TAVI, PCI was associated with a lower risk of a composite of death, MI, or urgent revascularization at a median of 2 years.
The New England Journal of Medicine: Search Results in Cardiology
Continuation versus Interruption of Oral Anticoagulation during TAVI
In a randomized trial involving patients undergoing TAVI, periprocedural continuation of oral anticoagulants was not noninferior to interruption of these drugs with respect to adverse events at 30 days.
The New England Journal of Medicine: Search Results in Cardiology